Notice of Allowance for US Patent

Allowance of US Patent on Isobaric Tandem Mass Tags              

                              TMT® Launch at ASMS                              

COBHAM, England (June 12, 2008) - Proteome Sciences plc ("Proteome Sciences")
is pleased to announce that the USPTO has issued a Notice of Allowance for its
US patent application in isobaric mass labelling for its tandem mass tags (TMT®) entitled
"Mass Labels" Serial No. 10/489/341 (TMT2). The Notice of Allowance completes
the final stage of patent examination and represents the form in which the
patent will be granted. This follows grants of the corresponding cases in
Europe, Australia and Canada. Issued patents are already granted for TMT1 in
the USA, Europe and other main jurisdictions.

Thermo Fisher Scientific, Inc. launched a range of TMT® products at the ASMS
mass spectrometry meeting in Denver, USA last week less than two months after
obtaining the exclusive license for isobaric tandem mass tag technology from
Proteome Sciences.

The high profile launch started with a well attended user meeting and was
accompanied and endorsed by 8 scientific posters/papers presented by Proteome
Sciences and a number of global scientific leaders in the field, confirming the
utility and performance of TMT/isobaric mass tags across a broad range of
different applications. These have been posted onto our website 
www.proteomics.com.

Commenting on the US Notice of Allowance and the TMT® launch. Christopher
Pearce, CEO of Proteome Sciences said:

"We are delighted to have received the Notice of Allowance for TMT2 in the US.
The patenting process for TMT1 and TMT2 is largely complete in the major
jurisdictions and we can look forward to seeing Thermo Fisher exploiting the
considerable opportunities from isobaric mass tags to deliver rapid biomarker
and assay solutions.

TMT® provides fast, flexible and cost effective workflows seamlessly from
biomarker discovery, through validation to clinical development and will
accelerate the utility and application of biomarkers in drug development and
diagnostics to make personalised medicine a reality"

                                     Ends                                      

About Proteome Sciences:

Proteome Sciences plc (LSE : PRM) is a global leader in applied proteomics,
using high sensitivity proprietary techniques to detect and characterise
differentially expressed proteins in diseases for diagnostic, prognostic and
therapeutic applications.

ProteoSHOP® provides integrated proteomic services for biomarker discovery,
validation and measurement in clinical trials and in vitro diagnostics. Key
features include the proprietary isobaric tandem mass tag technology TMT® for
accurate and reliable biomarker quantification and the ability to rapidly
develop highly reproducible quantitative biomarker assays.

The main focus of its research addresses neurological, oncology and
cardiovascular conditions and has discovered blood biomarkers in stroke, brain
damage, solid organ transplant rejection and Alzheimer's disease. Proteome
Sciences is based in Cobham, UK with facilities in London and Frankfurt.

Contact Proteome Sciences plc at www.proteomics.com

Christopher Pearce, Chief Executive Officer

James Malthouse, Finance Director

Dr. Ian Pike, Chief Business Officer

Tel: [phone]

Adrian Shaw, IKON Associates

Tel: [phone]

Matt Baldwin, COAST Communications

Tel: [phone]

Shaun Dobson, Landsbanki Securities (UK) Limited

Tel: [phone]